Opendata, web and dolomites

AntibioDx

AntibioDx: A groundbreaking in vitro diagnostic device with a billion-dollar sales potential

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "AntibioDx" data sheet

The following table provides information about the project.

Coordinator
STENDER HENRIK 

Organization address
address: FASANHAVEN 5
city: GENTOFTE
postcode: 2820
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2016-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STENDER HENRIK DK (GENTOFTE) coordinator 50˙000.00

Map

 Project objective

When diagnosing bloodstream infection (BSI), 19th century blood culture is essentially still the gold standard method - despite the highly critical 1-2 days delay from sample to result. Many cases of BSI remain undertreated in the early and highly critical stage of the infection and patients risk sepsis, which is among the 10 most common causes of death in hospitals and the most expensive condition to treat. AntibioDx is a device that will deliver the diagnostic capability needed in 21st century healthcare for preventing sepsis and reducing healthcare cost. It will provide doctors with information about the specific pathogen causing BSI and its antimicrobial-resistance profile within 1 hour. Personalised treatment with the most effective antimicrobial will replace empirical treatment using broad-spectrum antibiotics. Lives and money will be saved and the growing problem with resistance to antibiotics will be reduced. AntibioDx is a game changer with obvious gold standard and large sales potential. The clinical performance of the device is unrivalled and the possibility of using it with existing laboratory hardware facilitates full commercialisation in a market valued at 1 billion USD annually. Experienced clinicians have greeted the AntibioDx device with strong interest but final clinical validation studies is needed for taking significant commercial steps and realising full sales potential. The purpose of this Phase I application is to fully demonstrate proof-of-business and prepare the device for clinical validation as foundation for FDA approval. This work will be undertaken in collaboration with expert partners, including internationally renowned university hospitals in the EU and US.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANTIBIODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ANTIBIODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More